ReviewMolecular therapy. Oncology2026
Gene therapy as an upcoming technique in the treatment of cancer: A cellular solution to a cellular problem.
Review in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a formidable global health challenge, representing the second leading cause of mortality worldwide. In 2023, there were approximately 18.5 million new cancer cases and over 10 million deaths globally, with projections estimating 30.5 million new cases and 18.6 million deaths annually by 2050. In the US, an estimated 2,114,850 new cases and 626,140 deaths are projected for 2026. Cancer arises from accumulated genetic and epigenetic alterations that progressively transform normal cells into malignant counterparts, with mutations in proto-oncogenes, tumor suppressor genes, and DNA repair machinery as fundamental drivers of carcinogenesis. Gene therapy has emerged as a therapeutic modality that addresses cancer at its genetic core. This review examines the genetic basis of cancer pathogenesis and analyzes contemporary gene delivery platforms viral vectors, bacterial vectors (bactofection), physical methods (microinjection, electroporation, hydroporation, and gene gun), and chemical approaches (lipofection, polymer based systems, and nanoparticles)alongside their advantages, limitations, and clinical applications. Particular emphasis is placed on suicide gene therapy and immunomodulatory approaches, with focused examination of chimeric antigen receptor T cell (CAR-T) therapy as the most clinically advanced gene therapy strategy to date. Recent advances, including expanded regulatory designations for CAR-T therapies targeting solid tumors and next-generation vector platforms, underscore the field's rapid evolution. Despite persistent challenges safety concerns, high costs, and limited efficacy in solid tumors, gene therapy represents a transformative approach that may ultimately achieve durable remissions. We conclude by discussing future directions, including next-generation delivery systems, genome editing technologies such as CRISPR-Cas9 base and prime editing, and strategies to improve accessibility and affordability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.